Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers

NCT ID: NCT05938517

Last Updated: 2023-07-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-02
• Study Completion Date: 2021-10-14

Brief Summary

The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone.

The main questions it aims to answer are:

Is the plasma concentration of betahistine higher due to combination treatment with selegiline compared to betahistine monotherapy? How is the safety of the combination treatment with betahistine and selegiline, the pharmacokinetics of betahistine in different dosages in blood, and the inter-individual differences in the metabolism?

Subjects satisfying all selection criteria will receive three different dosages of Betahistine alone orally in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline orally. Plasma concentration (namely the AUC0-240min) of betahistine will be measured before and 10, 30, 60, 90, 120, 180, 240 minutes after treatment with blood examinations. Safety parameters include assessment of adverse events, ECG, vital signs, laboratory measurements including kidney and liver function, full blood count and pregnancy and drug screening test.

Detailed Description

This study was an investigator-initiated (IIT) prospective mono-center open-labeled trial to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone in healthy subjects.

Subjects were screened for their eligibility to participate in the study. Each subject gave written informed consent before any study-related procedures were performed.

Subjects satisfying all selection criteria were included in the open-labeled trial receiving 3 different dosages of Betahistine alone in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline. Betahistine serum concentrations were measured over a period of 240 min at 8 time points (area under the curve, AUC0-240 min). Safety parameters included assessment of adverse events, ECG, vital signs, laboratory measurements including kidney and liver function, full blood count and pregnancy and drug screening test). Safety monitoring was conducted during every visit and assessment of vital parameter and adverse events were conducted 10, 30, 60, 90, 120, 180, and 240min after betahistine intake. The clinical trial was conducted in a hospital of maximum care with the possibility to consult a specialist for possible symptoms of an intoxication especially an anesthesiologist, cardiologist and neurologist 24 hours/7 days a week.

Conditions

Ménière's Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Betahistine-dihydrochloride

Subjects received single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally for pharmacokinetic serum draw with at least two days between the different dosages.

Group Type: EXPERIMENTAL

Betahistine dihydrochloride

Intervention Type: DRUG

Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.

Betahistine-dihydrochloride and Selegiline-hydrochloride

Subjects were pre-treated with Selegiline (5 mg/day) orally for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally with at least two days between the different dosages.

Group Type: EXPERIMENTAL

Betahistine dihydrochloride

Intervention Type: DRUG

Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.

Selegiline-hydrochloride

Intervention Type: DRUG

In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.

Interventions

Betahistine dihydrochloride

Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.

Intervention Type: DRUG

Selegiline-hydrochloride

In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.

Intervention Type: DRUG

Other Intervention Names

Vasomotal; Selegiline-neuraxpharm

Eligibility Criteria

Inclusion Criteria

• Adult healthy volunteers, males and non-pregnant, non-breastfeeding woman with adequate contraception
• Healthy volunteers (age ≥ 18 years and ≤ 70 years) as determined by screening
• and Principal Investigator's judgement
• No intake of medication due to an illness
• Written informed consent of the subject
• Systolic blood pressure between 90 and 140 mmHg and diastolic blood pressure between 60 and 90 mmHg at screening
• PQ interval in the ECG between 0.12 s and 0.20 s
• Duration of the QRS complex between 0.06 s and 0.10 s
• QTc interval 440 ms or less
• Heart rate between 60 and 100 beats per minute
• Subjects with the ability to follow study instructions and likely to attend and complete all required visits

Exclusion Criteria

• Subject is not able to give consent
• A condition in which repeated serum draws or injections pose more than minimal risk for the subjects, such as haemophilia, other severe coagulation disorders or significantly impaired venous access
• Participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial
• Intake of medication due to an illness
• Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in the clinical trial before participation in this study
• Current or planned pregnancy or breastfeeding woman
• Woman of childbearing potential who is not willing to use medically reliable methods of contraception for the entire study duration
• Intake of alcohol 24 hours before first IMP intake or during study participation
• Known or persistent abuse of medication, drugs or alcohol (positive test for alcohol or drugs)
• Known contraindications for Betahistine, such as bronchial asthma, pheochromocytoma, treatment with antihistaminic drugs, ulcer of the stomach or duodenum, severe dysfunction of liver or kidney, hypersensitivity to Betahistine or other ingredients
• Known contraindications for Selegiline, e.g. use of opioids, tricyclic antidepressants, sympathomimetics, non-selective MAOIs, (selective) serotonin (-noradrenaline) re-uptake inhibitors (SSRI/SNRI), serotonin agonists, hypersensitivity to Selegiline or other ingredients
• Hereditary intolerance to galactose, hereditary deficiency of lactose, glucose-galactose-malabsorption
• AV Block in the ECG
• Hypotonic or hypertonic subjects according to the criteria of the National Heart, Lung and Serum Institute (Hypertension > 90/140 mmHg, Hypotension < 90/60 mmHg)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role: lead

Responsible Party

Prof. Dr. med. Michael Strupp

Senior physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Strupp, M.D.

Role: PRINCIPAL_INVESTIGATOR

LMU Munich

Locations

Department of Neurology, Ludwig Maximilian University

Munich, Bavaria, Germany

Countries

Germany

References

Strupp M, Churchill GC, Naumann I, Mansmann U, Al Tawil A, Golentsova A, Goldschagg N. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST). Front Neurol. 2023 Oct 18;14:1271640. doi: 10.3389/fneur.2023.1271640. eCollection 2023.

Reference Type: DERIVED

PMID: 37920833 (View on PubMed)

Other Identifiers

19-0992 fed

Identifier Type: -

Identifier Source: org_study_id